Urdea M S, Neuwald P D, Greenberg B L, Glick M, Galloway J, Williams D, Wong D T W
Halteres Associates LLC, 5858 Horton Street, Suite 280, Emeryville, CA 94608, USA.
Adv Dent Res. 2011 Oct;23(4):353-9. doi: 10.1177/0022034511420432.
Saliva, a scientific and clinical entity familiar to every oral health researcher and dental practitioner, has emerged as a translational and clinical commodity that has reached national visibility at the National Institutes of Health and the President's Office of Science and Technology. "Detecting dozens of diseases in a sample of saliva" was issued by President Obama as one of the 14 Grand Challenges for biomedical research in the 21(st) Century (National Economic Council, 2010). In addition, NIH's 2011 Government Performance Report Act (GPRA) listed 10 initiatives in the high-risk long-term category (Collins, 2011). The mandate is to determine the efficacy of using salivary diagnostics to monitor health and diagnose at least one systemic disease by 2013. The stage is set for the scientific community to capture these national and global opportunities to advance and substantiate the scientific foundation of salivary diagnostics to meet these goals. A specific calling is to the oral, dental, and craniofacial health community. Three areas will be highlighted in this paper: the concept of high-impact diagnostics, the role of dentists in diagnostics, and, finally, an infrastructure currently being developed in the United Kingdom--The UK Biobank--which will have an impact on the translational and clinical utilizations of saliva.
唾液,每位口腔健康研究人员和牙科从业者都熟知的一个科学和临床实体,已成为一种转化性和临床性商品,在美国国立卫生研究院和总统科学技术办公室已获得全国性关注。“在一份唾液样本中检测数十种疾病”被奥巴马总统列为21世纪生物医学研究的14项重大挑战之一(国家经济委员会,2010年)。此外,美国国立卫生研究院2011年的《政府绩效报告法案》(GPRA)在高风险长期类别中列出了10项举措(柯林斯,2011年)。任务是确定到2013年使用唾液诊断监测健康状况并诊断至少一种全身性疾病的有效性。科学界已做好准备,抓住这些国家和全球机遇,推进并夯实唾液诊断的科学基础,以实现这些目标。一个特定的呼吁是针对口腔、牙科和颅面健康领域的。本文将重点介绍三个方面:高影响力诊断的概念、牙医在诊断中的作用,以及最后,目前正在英国开发的一个基础设施——英国生物银行,它将对唾液的转化性和临床应用产生影响。